Reported 1 day ago
Morgan Stanley has reaffirmed its Buy rating for AbbVie Inc. (NYSE:ABBV), setting a price target of $250. The company's positive fiscal Q1 2025 results included a 6.5% growth in adjusted diluted EPS to $2.46 and a net revenue of $13.343 billion, marking an 8.4% increase. AbbVie continues to be a strong player in the pharmaceutical sector, specializing in treatments for chronic diseases.
Source: YAHOO